中和抗体与重症COVID-19进展保护:一项荟萃分析
该研究通过系统检索汇总25项临床研究数据,并与301项中和滴度研究匹配,用荟萃回归分析疫苗诱导中和抗体与重症COVID-19保护的关系。结果显示中和抗体滴度与疫苗保护进展至重症相关(RR 0.57每10倍GMT增加,95%CI 0.51-0.64,p<0.001),但疫苗保护高于治疗性被动抗体,提示其他免疫反应也起作用。
要点
- 中和抗体滴度每增加10倍,进展至重症COVID-19的相对风险为0.57(95%CI 0.51-0.64)。
- 疫苗对进展至重症的保护高于治疗性被动抗体治疗已感染者的保护。
- 中和抗体可部分解释疫苗保护机制,但其他免疫反应也可能参与。
核心结论
- 疫苗诱导的中和抗体与进展至重症COVID-19的保护相关,至少部分介导该保护。
- 疫苗保护高于治疗性被动抗体,提示其他免疫反应也发挥作用。
研究设计与样本
- 系统检索文献,汇总25项已发表临床研究评估疫苗对SARS-CoV-2感染者进展至重症(住院或ICU)的保护。
- 匹配301项研究的中和后滴度数据,来源为斯坦福大学冠状病毒抗病毒与耐药数据库。
- 采用荟萃回归合成数据。
主要发现
- 中和抗体滴度与疫苗保护进展至重症COVID-19相关:RR 0.57每10倍GMT增加,95%CI [0.51,0.64],p<0.001。
- 疫苗对进展的保护高于治疗性被动抗体用于已确诊感染者的保护。
临床怎么用
- 中和抗体滴度可作为评估疫苗对重症保护效果的参考指标。
- 疫苗对重症的保护不能仅归因于中和抗体,需综合考虑其他免疫反应。
局限性
- 中和滴度与临床结局在不同研究中测量。
- 可能存在未测量的混杂因素。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Vaccine-induced neutralising antibodies are a well-established correlate of protection against acquisition of COVID-19. Vaccine protection from severe COVID-19 remains high, although the role of neutralising antibodies and the contribution of other immune responses to protection from severe outcomes is less clear. Improving understanding of how vaccines prevent severe outcomes is important for future vaccine development. METHODS AND FINDINGS: Here we undertake a systematic search of the literature to obtain estimates of vaccine protection against progression from SARS-CoV-2 infection to severe COVID-19 (hospital or ICU admission). We aggregate results from 25 published clinical studies of vaccine protection from progression to severe outcomes in people with SARS-CoV-2 infection. We match this clinical data to data from 301 studies of post-vaccination neutralisation titres induced by various vaccines against different SARS-CoV-2 variants from the publicly available Stanford University Coronavirus antiviral and resistance database. We then synthesise the data using meta-regression. Neutralising antibody titres were found to be associated with vaccine protection against progression to severe COVID-19 (relative risk (RR) 0.57 per 10-fold increase in GMT, 95% CI [0.51,0.64], p < 0.001). We found that the protection against progression provided by vaccination was higher than that provided by therapeutic passive administration of antibodies, when used to treat individuals with confirmed infection. The main methodological limitations were the fact that neutralisation titres and clinical outcomes were measured in different studies, and the possibility of unmeasured confounding. CONCLUSIONS: Together, this work suggests that vaccine-induced neutralising antibodies are correlated with protection from progression to severe COVID-19 and can account for at least a partial mechanistic role in this protection. However, a protection gap remains between the high levels of protection against progressing to severe COVID-19 afforded by vaccination, compared to that afforded by therapeutic administration of antibodies, suggesting other immune responses may also play a role.
引用
- Elias KM, Mitchell A, Stadler E, et al. Neutralising antibodies and protection from progression to severe COVID-19: A meta-analysis. PLoS Med. 2026. PMID: 42685247. doi:10.1371/journal.pmed.1005230
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。